Abstract
Objective: To assess the cardiovascular and metabolic responses to increasing doses of formoterol administered from a dry powder inhaler. Methods: Twenty patients with mild to moderate asthma were given 12, 24, 48 and 96 μg of formoterol or a matched placebo on separate days. The doses were administered using a randomised, cross-over, double-blind design. The effects on heart rate, blood pressure, electromechanical systole (QS2I), the electrocardiographic QTc interval, plasma potassium (K); blood glucose and FEV1 were assessed prior to, and for 9 h following each dose. Results: There was no difference between the maximum effects of formoterol 12 μg and placebo; the 24 μg dose significantly decreased plasma K (−0.2 mmol · l−1) and increased blood glucose (1.8 mmol · l−1) compared to placebo. The two highest doses affected most of the variables with the 96 μg dose being significantly different from placebo for all indices, heart rate (9 beats · min−1), systol BP (4 mmHg), diastolic BP (−3 mmHg), QS2I (−11 ms), QTc (17 ms), plasma K (−0.5 mmol · l−1) and blood glucose (2.6 mmol · l−1). All doses of formoterol increased FEV1. Conclusion: Although there were dose-dependent effects on the extrapulmonary measurements, only the effects at the highest dose may be of clinical significance.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 17 June 1997 / Accepted in revised form: 12 November 1997
Rights and permissions
About this article
Cite this article
Burgess, C., Ayson, M., Rajasingham, S. et al. The extrapulmonary effects of increasing doses of formoterol in patients with asthma. E J Clin Pharmacol 54, 141–147 (1998). https://doi.org/10.1007/s002280050435
Issue Date:
DOI: https://doi.org/10.1007/s002280050435